Synlogic to Merge with Caldera Therapeutics, Securing $278M Financing and Nasdaq Relisting
SYBX sits 33% above its 52-week low of $0.54 on elevated volume (5.0× avg).
Summary
Synlogic, Inc. announced a definitive merger agreement with Caldera Therapeutics, Inc., valuing Synlogic at an $18.0 million premium, securing $278.0 million in concurrent financing, and planning a Nasdaq relisting for the combined entity.
Updates
· SEC SCHEDULE 13D/A — A 28.3% shareholder bloc, Funicular Funds and Cable Car Capital, signed a support agreement to vote for the merger and granted an irrevocable proxy.
Key Events · M&A and Partnerships · SYBX
-
Definitive Merger Agreement
Synlogic, Inc. will merge with Caldera Therapeutics, Inc., with both becoming wholly-owned subsidiaries of a new holding company, Sonic Holdco, Inc. The combined entity will operate as Caldera Therapeutics, Inc.
-
Significant Valuation Premium
Synlogic is valued at $18.0 million in the merger, more than double its current market capitalization of $8.42 million. Existing Synlogic shareholders are expected to own approximately 2.3% of the combined company.
-
Concurrent Private Placement
Caldera has secured commitments for an upsized $278.0 million private placement, expected to close concurrently with the merger. This financing is projected to fund the combined company's operations into 2029.
-
Nasdaq Relisting Plan
The combined company intends to apply to trade on the Nasdaq Capital Market under the ticker symbol 'CALD', providing a path for Synlogic, currently on OTC Pink, to return to a major exchange.
Analysis · SYBX · Life Sciences
This is a transformative event for Synlogic, Inc., which has been operating as a delisted shell company. The merger with Caldera Therapeutics values Synlogic at $18.0 million, representing a significant premium over its current market capitalization of $8.42 million. While existing Synlogic shareholders will own a small percentage (2.3%) of the combined entity, this is a stake in a much larger, well-funded company with a clear path to relisting on Nasdaq. The concurrent $278.0 million private placement provides substantial capital, extending the combined company's cash runway into 2029, which is critical for advancing Caldera's clinical pipeline. The reduction in exercise price for existing Synlogic warrants will lead to dilution but is part of the overall transaction to recapitalize and reposition the company.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 41% of the 324 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.33%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SYBX was trading at $0.72 on OTC in the Life Sciences sector, with a market capitalization of approximately $8.4M. The 52-week trading range was $0.54 to $1.96. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.